AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
AGIO on Nasdaq
Shares outstanding
58,643,980
Price per share
$27.22
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
63,492,585
Total reported value
$2,545,823,532
% of total 13F portfolios
0%
Share change
+1,630,536
Value change
+$81,769,921
Number of holders
215
Price from insider filings
$27.22
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Farallon Capital Partners, L.P. 9.9% $149,124,966 5,674,466 Dapice Joshua J. 31 Dec 2024
BlackRock, Inc. 7.8% $123,299,804 4,513,170 BlackRock, Inc. 30 Jun 2025
Paradigm Biocapital Advisors LP 4.9% -6% $115,344,498 -$6,198,499 2,873,555 -5.1% Paradigm BioCapital Advisors LP 30 Sep 2025

As of 30 Sep 2025, 215 institutional investors reported holding 63,492,585 shares of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO). This represents 108% of the company’s total 58,643,980 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) together control 86% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FARALLON CAPITAL MANAGEMENT LLC 9.9% 5,781,066 +0.24% 1.3% $232,051,989
VANGUARD GROUP INC 9.6% 5,604,876 -1.4% 0% $224,979,722
BlackRock, Inc. 7.8% 4,545,738 -6% 0% $182,465,924
Bellevue Group AG 6.3% 3,714,736 +3.5% 3.1% $149,109,503
Erste Asset Management GmbH 4.7% 2,764,900 +19% 1% $108,577,623
Paradigm Biocapital Advisors LP 4.6% 2,673,555 +134% 3.2% $107,316,498
WELLINGTON MANAGEMENT GROUP LLP 4.2% 2,471,416 +485% 0.02% $99,202,637
Commodore Capital LP 4% 2,338,287 +0.57% 4.6% $93,858,840
STATE STREET CORP 3.9% 2,262,712 +16% 0% $90,825,260
MACQUARIE GROUP LTD 3.3% 1,958,101 +3% 0.09% $78,598,000
PRICE T ROWE ASSOCIATES INC /MD/ 2.8% 1,656,938 -27% 0.01% $66,510,000
TCG Crossover Management, LLC 2.4% 1,430,041 +105% 2.8% $57,401,846
GEODE CAPITAL MANAGEMENT, LLC 2.4% 1,416,315 +0.75% 0% $56,859,764
Frazier Life Sciences Management, L.P. 2.2% 1,279,754 0% 1.5% $51,369,326
Caligan Partners LP 1.9% 1,131,205 +5.6% 6.3% $45,406,569
BANK OF AMERICA CORP /DE/ 1.9% 1,130,000 +0.87% 0% $45,358,199
DIMENSIONAL FUND ADVISORS LP 1.7% 1,021,201 -7.7% 0.01% $40,987,144
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.7% 987,339 -2.9% 0.1% $39,631,000
Rock Springs Capital Management LP 1.6% 958,542 -3.2% 2.2% $38,475,876
DEUTSCHE BANK AG\ 1.6% 926,734 +0.56% 0.01% $37,199,103
Fisher Asset Management, LLC 1.5% 870,145 -0.84% 0.01% $34,927,619
GW&K Investment Management, LLC 1.5% 852,942 -1.8% 0.3% $34,238,000
GOLDMAN SACHS GROUP INC 1.4% 804,766 +24% 0% $32,303,307
ADAGE CAPITAL PARTNERS GP, L.L.C. 1.4% 800,000 +1.1% 0.05% $32,112,000
ARMISTICE CAPITAL, LLC 1.3% 764,000 -35% 0.96% $30,666,960

Institutional Holders of AGIOS PHARMACEUTICALS, INC. - Common Stock (AGIO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 172,507 $4,695,245 +$2,100,317 $27.22 7
2025 Q3 63,492,585 $2,545,823,532 +$81,769,921 $40.14 215
2025 Q2 61,683,672 $2,051,725,997 +$65,237,833 $33.26 211
2025 Q1 59,963,279 $1,757,321,769 -$10,187,071 $29.30 216
2024 Q4 59,832,442 $1,966,430,386 +$43,737,817 $32.86 221
2024 Q3 57,920,716 $2,574,454,821 -$15,898,419 $44.43 206
2024 Q2 58,137,954 $2,507,151,009 -$113,308,908 $43.12 205
2024 Q1 61,675,983 $1,803,348,703 +$64,511,304 $29.24 184
2023 Q4 2,262,303 $50,416,797 +$11,750,679 $22.27 3
2023 Q3 57,169,946 $1,415,017,058 -$4,958,129 $24.75 139
2023 Q2 57,468,940 $1,626,096,955 +$12,169,342 $28.32 148
2023 Q1 57,257,345 $1,315,213,956 -$9,971,782 $22.97 159
2022 Q4 57,685,708 $1,619,825,989 +$41,423,722 $28.08 153
2022 Q3 52,651,670 $1,489,020,878 -$7,966,295 $28.28 148
2022 Q2 56,852,821 $1,258,863,058 -$31,593,203 $22.17 137
2022 Q1 57,837,003 $1,683,501,435 +$21,351,741 $29.11 139
2021 Q4 57,260,860 $1,882,115,980 -$91,300,379 $32.87 144
2021 Q3 59,722,525 $2,756,230,963 -$246,955,392 $46.15 155
2021 Q2 64,818,408 $3,571,542,082 +$49,489,403 $55.11 177
2021 Q1 64,197,613 $3,312,467,222 +$57,879,032 $51.64 167
2020 Q4 63,834,095 $2,765,934,080 -$17,892,334 $43.33 184
2020 Q3 64,490,285 $2,256,153,435 -$115,138,566 $35.00 201
2020 Q2 66,577,123 $3,560,517,100 -$65,381,817 $53.48 200
2020 Q1 68,225,174 $2,420,555,889 +$8,749,457 $35.48 181
2019 Q4 67,905,503 $3,242,333,402 +$336,999,734 $47.75 186
2019 Q3 61,053,778 $1,978,163,042 +$38,658,492 $32.40 173
2019 Q2 59,897,807 $2,987,491,273 +$322,164,396 $49.88 179
2019 Q1 59,557,918 $4,016,974,892 +$161,713,085 $67.44 188
2018 Q4 57,445,702 $2,648,765,084 +$49,982,621 $46.11 179
2018 Q3 55,672,631 $4,289,775,406 +$92,832,901 $77.12 199
2018 Q2 54,417,973 $4,583,620,355 -$2,797,515 $84.23 206
2018 Q1 54,875,591 $4,484,038,749 +$716,756,813 $81.78 193
2017 Q4 47,030,080 $2,686,215,197 +$50,537,727 $57.17 174
2017 Q3 46,098,306 $3,074,260,539 +$17,987,931 $66.75 169
2017 Q2 46,167,957 $2,373,358,886 +$269,224,232 $51.45 165
2017 Q1 41,010,099 $2,392,727,570 +$240,618,963 $58.40 154
2016 Q4 38,895,903 $1,621,759,134 +$47,855,886 $41.73 152
2016 Q3 37,863,493 $1,992,276,770 +$250,616,602 $52.82 161
2016 Q2 34,064,555 $1,424,544,193 +$19,597,005 $41.89 150
2016 Q1 33,761,359 $1,370,476,373 +$17,790,924 $40.60 146
2015 Q4 33,001,053 $2,142,549,128 +$93,232,576 $64.92 138
2015 Q3 31,387,745 $2,215,538,820 +$86,489,924 $70.59 148
2015 Q2 29,967,566 $3,330,230,014 +$252,450,809 $111.14 159
2015 Q1 27,941,247 $2,635,167,051 -$36,991,516 $94.30 149
2014 Q4 27,639,503 $3,096,870,918 +$394,968,512 $112.04 144
2014 Q3 24,482,713 $1,502,054,443 +$80,445,934 $61.35 119
2014 Q2 23,577,523 $1,080,167,790 +$140,723,750 $45.82 98
2014 Q1 20,545,950 $804,373,483 +$94,023,723 $39.15 73